Rocket Pharmaceuticals Inc (RCKT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Gaurav D. Shah
Employees:
240
430 EAST 29TH STREET, SUITE 1040, NEW YORK, NY 10016
646-440-9100

Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells. The company also has a clinical stage in vitro virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure.

Data derived from most recent annual or quarterly report
Market Cap 1.682 Billion Shares Outstanding79.348 Million Avg 30-day Volume 690.094 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.87
Price to Revenue0.0 Debt to Equity0.0 EBITDA-240.122 Million
Price to Book Value2.966 Operating Margin0.0 Enterprise Value1.001 Billion
Current Ratio10.832 EPS Growth-0.234 Quick Ratio10.61
1 Yr BETA 1.8092 52-week High/Low 23.48 / 9.5 Profit Margin0.0
Operating Cash Flow Growth-44.3605 Altman Z-Score11.6649 Free Cash Flow to Firm -198.589 Million
Earnings Report2023-08-07
View SEC Filings from RCKT instead.

View recent insider trading info

Rocket Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RCKT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RCKT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-19 by SHAH GAURAV
  • 4: filed on 2023-05-16 by SHAH GAURAV
  • 4: filed on 2023-05-16 by MILITELLO JOHN
  • 4: filed on 2023-05-16 by PATEL KINNARI
  • 4: filed on 2023-04-25 by MILITELLO JOHN
  • 4: filed on 2023-04-20 by MILITELLO JOHN
  • 4: filed on 2023-04-12 by WHITE MARK ANDREW
  • 3: filed on 2023-04-12 by WHITE MARK ANDREW
  • 4: filed on 2023-04-05 by RTW INVESTMENTS, LP
  • 4: filed on 2023-02-22 by Schwartz Jonathan David

    • Events (8k)

  • 8-K: filed on 2023-04-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-02-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-01:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-17:
  • 144: filed on 2023-05-17:
  • 144: filed on 2023-05-17:
  • 144: filed on 2023-05-17:
  • 144: filed on 2023-04-21:
  • 144: filed on 2023-04-13:
  • 144: filed on 2023-04-11:
  • 144: filed on 2023-04-06:
  • 144: filed on 2023-03-31:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    8 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    19.1 Thousand total shares from 4 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MILITELLO JOHN SEE REMARKS

    • Officer
    		 6,116 2023-05-17 8

    SHAH GAURAV CEO

    • Officer
    • Director
    		 927,880 2023-05-17 5

    PATEL KINNARI SEE REMARKS

    • Officer
    		 317,929 2023-05-17 5

    WHITE MARK ANDREW CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-04-04 2

    SCHWARTZ JONATHAN DAVID SEE REMARKS

    • Officer
    		 94,546 2023-02-17 4

    WILSON MARTIN GENERAL COUNSEL

    • Officer
    		 0 2023-02-14 2

    RTW INVESTMENTS, LP

    WONG RODERICK

    • Director
    • 10% Owner
    • SEE REMARKS
    		17,628,567 2022-12-23 3

    GRANADILLO PEDRO P

    • Director
    		 58,028 2022-06-13 1

    SOUTHWELL DAVID P

    • Director
    		 142,905 2022-06-13 1

    BOESS CARSTEN

    • Director
    		 47,745 2022-06-13 1

    WONG RODERICK

    • Director
    • 10% Owner
    		 53,621 2022-06-13 1

    MALIK FADY IBRAHAM

    • Director
    		 47,745 2022-06-13 1

    YALAMANCHI NAVEEN

    • Director
    		 130,136 2022-06-13 1

    MAKKER GOTHAM

    • Director
    		 728,522 2022-06-13 1

    BJORK ELISABETH

    • Director
    		 55,090 2022-06-13 1

    GARCIA-PARADA CARLOS CHIEF FINANCIAL OFFICER

    • Officer
    		 71,328 2022-02-14 0

    WONG RODERICK

    RTW INVESTMENTS, LP

    YALAMANCHI NAVEEN

    • Director
    • 10% Owner
    		 16,272,635 2021-08-27 3

    ALAM KAMRAN SVP - FINANCE & PFO

    • Officer
    		 0 2020-02-06 0

    BATCHELDER BRIAN SEE REMARKS

    • Officer
    		 0 2018-01-04 0

    RITTER DALE VICE PRESIDENT, FINANCE

    • Officer
    		 19,827 2017-09-14 0

    BARBERICH TIMOTHY J

    • Director
    		 0 2017-06-20 0

    PHILLIPS GARY M.

    • Director
    		 0 2017-06-20 0

    HOWES PAUL G

    • Director
    		 0 2017-06-20 0

    CARROLL J MARTIN

    • Director
    		 0 2017-06-20 0

    MACHADO PATRICK

    • Director
    		 0 2017-06-20 0

    SPIVEY RICHARD N.

    • Director
    		 0 2017-06-20 0

    BAUMGARTNER RUDOLF A SEE REMARKS

    • Officer
    		 0 2017-01-23 0

    DEVON PARK BIOVENTURES LP

    DEVON PARK ASSOCIATES, L.P.

    DEVON PARK ASSOCIATES, LLC

    • 10% Owner
    		 No longer subject to file 2017-01-04 0

    MCVICAR WILLIAM K. SEE REMARKS

    • Officer
    		 0 2016-03-22 0

    RHO VENTURES IV HOLDINGS LLC

    RHO VENTURES IV-A, L.P.

    • 10% Owner
    		 No longer subject to file 2015-11-16 0

    DEVON PARK ASSOCIATES, L.P.

    DEVON PARK ASSOCIATES, LLC

    KANTESARIA DEVANG

    • 10% Owner
    		 3,253,566 2015-07-14 0

    KARABELAS ARGERIS N

    • Director
    • 10% Owner
    		 0 2015-06-24 0

    CARE CAPITAL II LLC

    CARE CAPITAL INVESTMENTS II LP

    CARE CAPITAL OFFSHORE INVESTMENTS II LP

    CARE CAPITAL III LLC

    CARE CAPITAL INVESTMENTS III L.P.

    CARE CAPITAL OFFSHORE INVESTMENTS III LP

    • 10% Owner
    		 0 2015-06-24 0

    VOGELBAUM MARTIN

    • Director
    		 0 2015-06-24 0

    PEIMER ISAI

    • Director
    		 0 2015-06-24 0

    HAREL ITTAI

    • Director
    		 0 2015-06-24 0

    RHO VENTURES IV QP LP

    RHO VENTURES IV GMBH & CO BETEILIGUNGS KG

    RHO VENTURES IV HOLDINGS LLC

    RHO VENTURES IV LP

    RHO VENTURES IV-A, L.P.

    RHO MANAGEMENT VENTURES IV LLC

    RHO CAPITAL PARTNERS VERWALTUNGS GMBH

    KAIROUZ HABIB

    RUCH JOSHUA

    LESCHLY MARK

    • 10% Owner
    		 6,622,208 2015-02-23 0

    PITANGO VENTURE CAPITAL PRINCIPALS FUND IV, L.P.

    PITANGO VENTURE CAPITAL FUND IV, L.P.

    PITANGO V.C. FUND IV, L.P.

    PITANGO G.C. CAPITAL HOLDINGS LTD.

    • 10% Owner
    		 3,414,859 2015-02-23 0

    MEDIMMUNE VENTURES, INC.

    • 10% Owner
    		 4,863,180 2015-02-23 0

    KANTESARIA DEVANG

    • 10% Owner
    		 7,996,862 2015-02-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SHAH GAURAV - Director - Officer CEO

    		2023-05-19 16:05:38 -0400 2023-05-17 S 4,122 $21.38 d 521,642 direct 1.5062 1.5062 2 0.0 1

    PATEL KINNARI - Officer SEE REMARKS

    		2023-05-19 16:05:32 -0400 2023-05-17 S 1,330 $21.38 d 213,993 direct 1.5062 1.5062 2 0.0 1

    MILITELLO JOHN - Officer SEE REMARKS

    		2023-05-19 16:05:30 -0400 2023-05-17 S 245 $21.38 d 6,116 direct 1.5062 1.5062 2 0.0 1

    PATEL KINNARI - Officer SEE REMARKS

    		2023-05-16 19:57:09 -0400 2023-05-14 M 3,989 a 215,323 direct -1.2523 -0.0928 3.154 5 -1.2523 2

    PATEL KINNARI - Officer SEE REMARKS

    		2023-05-16 19:57:09 -0400 2023-05-14 M 3,989 d 27,982 direct

    MILITELLO JOHN - Officer SEE REMARKS

    		2023-05-16 20:01:55 -0400 2023-05-14 M 725 a 6,361 direct -1.2523 -0.0928 3.154 5 -1.2523 2

    MILITELLO JOHN - Officer SEE REMARKS

    		2023-05-16 20:01:55 -0400 2023-05-14 M 725 d 5,078 direct

    SHAH GAURAV - Director - Officer CEO

    		2023-05-16 20:04:37 -0400 2023-05-14 M 7,979 a 525,764 direct -1.2523 -0.0928 3.154 5 -1.2523 2

    SHAH GAURAV - Director - Officer CEO

    		2023-05-16 20:04:37 -0400 2023-05-14 M 7,979 d 55,856 direct

    MILITELLO JOHN - Officer SEE REMARKS

    		2023-04-25 18:33:13 -0400 2023-04-21 S 2,342 $18.65 d 5,636 direct -0.5705 1.312 4.4495 4 -0.5705 2

    MILITELLO JOHN - Officer SEE REMARKS

    		2023-04-20 18:34:38 -0400 2023-04-18 M 6,364 a 7,978 direct -1.6181 -3.3441 0.0 1 -5.9871 5

    MILITELLO JOHN - Officer SEE REMARKS

    		2023-04-20 18:34:38 -0400 2023-04-18 M 6,364 a 12,670 direct

    WHITE MARK ANDREW - Officer CHIEF MEDICAL OFFICER

    		2023-04-12 19:00:22 -0400 2023-04-04 A 57,739 a 57,739 direct

    WHITE MARK ANDREW - Officer CHIEF MEDICAL OFFICER

    		2023-04-12 19:00:22 -0400 2023-04-04 A 76,662 a 76,662 direct -3.2013 0.6511 13.2393 20.6728 29 -5.4259 11

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 22:15:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 21:45:05 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 21:15:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 20:45:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 20:15:05 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 19:45:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 19:15:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 18:45:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 18:15:03 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 17:45:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 17:15:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 16:45:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 16:15:03 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 15:45:03 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 15:15:03 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 14:45:05 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 14:15:04 UTC 4.8053 0.2647 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 13:45:05 UTC 4.8168 0.2532 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 13:15:03 UTC 4.8168 0.2532 2300000
    ROCKET PHARMACEUTICALS INC RCKT 2023-05-29 12:45:03 UTC 4.8168 0.2532 2300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund RCKT -12.0 shares, $-167.4 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund RCKT -21.0 shares, $-292.95 2020-03-31 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund RCKT -6494.0 shares, $-103644.24 2022-09-30 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund RCKT -1172.0 shares, $-25467.56 2023-01-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments